History of meningococcal vaccines and their serological correlates of protection

被引：52

作者：

Vipond, Caroline ^{[1
]}

Care, Rory ^{[1
]}

Feavers, Ian M. ^{[1
]}

机构：

[1] NIBSC, Div Bacteriol, Potters Bar EN6 3QG, Herts, England

来源：

VACCINE | 2012年 / 30卷

关键词：

Vaccine; Meningitis; Polysaccharide; Outer membrane vesicle; Serological correlate; Complement; Bactericidal antibody; Gene expression; OUTER-MEMBRANE PROTEIN; C CONJUGATE VACCINE; MENINGITIDIS GROUP-B; FACTOR-H BINDING; NEISSERIA-MENINGITIDIS; SEROGROUP-C; GROUP-A; IMMUNE-RESPONSE; VESICLE VACCINE; POLYSACCHARIDE VACCINE;

D O I：

10.1016/j.vaccine.2011.12.060

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

For over a hundred years Neisseria meningitidis has been known to be one of the major causes of bacterial meningitis. However, effective vaccines were not developed until the latter part of the 20th century. The first of these were based on purified high molecular weight capsular polysaccharides and more recently the development of glycoconjugate vaccines has made paediatric immunisation programmes possible. The prevention of group B meningococcal disease has remained a challenge throughout this period. This review charts the history of the development of meningococcal vaccines and the importance of serological correlates of protection in their evaluation. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：B10 / B17

页数：8

共 125 条

[71] Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story [J].

Miller, E ;

Salisbury, D ;

Ramsay, M .

VACCINE, 2001, 20 :S58-S67

[72] IMMUNITY AND PROTECTION OF MICE AGAINST NEISSERIA-MENINGITIDIS GROUP-B BY VACCINATION, USING POLYSACCHARIDE COMPLEXED WITH OUTER-MEMBRANE PROTEINS - A COMPARISON WITH PURIFIED B-POLYSACCHARIDE [J].

MORENO, C ;

LIFELY, MR ;

ESDAILE, J .

INFECTION AND IMMUNITY, 1985, 47 (02) :527-533

[73] The impact of Hib conjugate vaccines in preventing invasive H-influenzae diseases in the UK [J].

Moxon, ER ;

Heath, PT ;

Booy, R ;

Azzopardi, HJ ;

Slack, MPE ;

Ramsay, ME .

VACCINE, 1999, 17 :S11-S13

[74]

Næss LM, 1999, VACCINE, V17, P754, DOI 10.1016/S0264-410X(98)00259-X

[75] Crystal structure of an anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design [J].

Oomen, CJ ;

Hoogerhout, P ;

Kuipers, B ;

Vidarsson, G ;

van Alphen, L ;

Gros, P .

JOURNAL OF MOLECULAR BIOLOGY, 2005, 351 (05) :1070-1080

[76] Expression of Factor H Binding Protein of Meningococcus Responds to Oxygen Limitation through a Dedicated FNR-Regulated Promoter [J].

Oriente, Francesca ;

Scarlato, Vincenzo ;

Delany, Isabel .

JOURNAL OF BACTERIOLOGY, 2010, 192 (03) :691-701

[77] Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand [J].

Oster, P. ;

O'Hallahan, J. ;

Aaberge, I. ;

Tilman, S. ;

Ypma, E. ;

Martin, D. .

VACCINE, 2007, 25 (16) :3075-3079

[78] MeNZB™:: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain [J].

Oster, P ;

Lennon, D ;

O'Hallahan, J ;

Mulholland, K ;

Reid, S ;

Martin, D .

VACCINE, 2005, 23 (17-18) :2191-2196

[79] Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine [J].

Peeters, CCAM ;

Rumke, HC ;

Sundermann, LC ;

vanderVoort, EMR ;

Meulenbelt, J ;

Schuller, M ;

Kuipers, AJ ;

vanderLey, P ;

Poolman, JT .

VACCINE, 1996, 14 (10) :1009-1015

[80]

PELTOLA H, 1983, REV INFECT DIS, V5, P71

← 3 4 5 6 7 8 9 10 11 12 →